neuroendocrine tumors (NENs) is a kind of neuroendocrine tumors that are mainly differentiated from neuroendocrine. More than 80% of NEN can highly express somatostatin receptor (somatostatin receptor, SSTR) , which makes SSTR-mediated radionuclide therapy (peptide receptor radionuclides therapy, PRRT) It is possible to treat NENs with .
177Lu-labeled somatostatin analogue octreotide 8 (177Lu-DOTAs-TATE is currently the most radioactive drug in clinical use). However, 177Lu-DOTA-TATE can be quickly cleared from the blood by the kidneys, and it does not stay in the tumor lesions. Compared with 177Lu-DOTA-TATE, 177Lu-DOTA-EB-TATE uses Evans Blue (Evans blue, EB) structure to reversibly bind albumin in plasma,Effectively prolong its half-life in the blood to increase the accumulation and retention of targeting of radiopharmaceuticals in the tumor.
Peking Union Medical College Hospital Zhu Zhaohui Professor and the National University of Singapore strong8span _span12 Chenspan strong8span strong8span_span12 177 Lu-DOTA-EB-TATE treatment of NENs related research. Recently, the team published an article in the journal The Journal of Nuclear Medicine Journal The Journal of Nuclear Medicine -DOTA-EB-TATE . The United States Nuclear Medicine and the Society of Molecular Imaging (SNMMI) also issued a press release _morspan More Strong Treatments _morspan Newstrong Treatments_strong_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span_span , focusing on recommending the article published by the team in JNM journal, and affirmed that 177Lu-DOTA-EB-TATE is a more effective, safer and more economical new type of radiotherapy for patients with neuroendocrine tumor .
This article randomly divides 32 patients with late-advanced NENs who receive 177 Lu-DOTA-EB treatment courses into 3 groups at random. The results show that the disease control rate of the lower dose of 177Lu-DOTA-EB-TATE (disease control rate, DCR) is equivalent to the standard dose of 177Lu-DOTA-TATE.And there is no significant increase in toxic and side effects, and the liver and kidney functions are hardly affected. 1.89 GBq/course (about 50 mCi/course) group, the incidence of blood toxicity of grade 3 and above is about 16.6%; 3.97 GBq/course (about 100 mCi/course) group The incidence of blood toxicity of grade 3 and above is about 21.4%. 177Lu-DOTA-EB-TATE has the best tumor control effect and the lowest risk when the dose is 1.89 GBq/course. They also pointed out that through careful patient selection and monitoring, 3.97 GBq/course of treatment is expected to achieve a better curative effect without obvious side effects.
Figure: representative images of partial remission after treatment. (A) Group A; (B) Group B; (C) Group C.
National University of Singapore Yang Luling School of Medicine/School of Engineering dual-appointed lifelong chair professor Chen Xiaoyuan said, " For NENs patients, the more efficiently we can use 177Lu for treatment, the more we can reduce the use of 177Lu for treatment. The economic pressure of patients. In general, 177Lu-DOTA-EB-TATE, a new type of radiotherapy drug, may potentially affect the mortality of NENs patients." . He went on to say, "Now we understand the role of EB remodeling in the treatment of NENs,We hope that it can be restructured to create more new types of radiopharmaceuticals suitable for other types of tumor treatment in the future. "_Span12span
177Lu-DOTA-EB-TATE This new radiotherapy drug has been fully licensed to the American Molecular Targeting Technologies company (Molecular Targeting Technologies, Inc., MTTI) , and its new drug clinical trial application (IND) has been approved by the US Food and Drug Administration (FDA) . MTTI President and CEO Bai Guanren (Chris Pak) Dr. said, "This is an exciting step change in neuroendocrine tumor management. Effective, potentially less toxic, and low-dose 177Lu-DOTA-EB-TATE has great application prospects in patients with neuroendocrine tumors. "_Span12span
original link:
https://jnm.snmjournals.org/content/62/3/386
press release link :
https://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=36701
people plate: eleven
Reprint Notice
[Non-original article] The copyright of this article belongs to the author of the article,Personal reposting and sharing are welcome. Reprinting is prohibited without permission. The author has all legal rights, and offenders must be investigated.
.
